Fundraising Fox
RenBio
Long Island City, US · Founded 2020 · Delaware corporation
Find your way into RenBio
Sign up to find every way you can get introduced to RenBio
- Your email: who you already know at RenBio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the RenBio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
RenBio develops DNA-based therapeutic technology that uses intramuscular injection of therapeutic-encoding "bioblueprints" so a patient's own muscle cells produce antibodies and therapeutic proteins to prevent and treat diseases, including infectious diseases. The company works in the antibody and therapeutic protein field, aiming to overcome obstacles in delivery, durability, and cost.
Founders & leadership
RenBio was founded in 2020 by David Ho and Yaoxing Huang.
DH
David HoCo-founder
YH
Yaoxing HuangCo-founder
RA
Rachel A. Liberatore, Ph.D.Executive
NP
Neal PadteNamed on SEC filing
CC
Chi-Chuan ChenNamed on SEC filing
DC
David ChuNamed on SEC filing
TT
Tamon TsengNamed on SEC filing
WF
Wan Feng TingNamed on SEC filing
Board
DT
Donald TangBoard director
WW
Walter Wang, Sr.Board director
JG
Jaap Goudsmit, M.D., Ph.D.Board director
Reported raises · per SEC filings
Form D private placements$19.3M disclosed across 2 rounds · 2020–2024
▶$5.3MraisedSep 2024 · 7 investors · BiotechnologyRule 506(b)
▶$5.3MraisedSep 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jaap Goudsmit, M.D., Ph.D.Director
- Rachel A. Liberatore, Ph.D.Director, Executive Officer
- Zhi Hong, Ph.D.Director
- Donald TangDirector
- Annelyn O'RourkeExecutive Officer
- Walter Wang, Sr.Director
- Offering amount
- $6M
- Amount sold
- $5.3M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$14MraisedJan 2021 · 7 investors · BiotechnologyRule 506(b)
▶$14MraisedJan 2021 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neal PadteExecutive Officer, Director
- Chi-Chuan ChenDirector
- David ChuDirector
- Tamon TsengDirector
- Wan Feng TingDirector
- Offering amount
- $24M
- Amount sold
- $14M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Dren BioDren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
Regenx BiosciencesREGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.
Companies working in the same space as RenBio.
In the news
Frequently asked questions
- What does RenBio do?
- RenBio develops DNA-based therapeutic technology that uses intramuscular injection of therapeutic-encoding "bioblueprints" so a patient's own muscle cells produce antibodies and therapeutic proteins to prevent and treat diseases, including infectious diseases. The company works in the antibody and therapeutic protein field, aiming to overcome obstacles in delivery, durability, and cost.
- Who founded RenBio?
- RenBio was founded by David Ho, Yaoxing Huang in 2020.
- How much funding has RenBio raised?
- RenBio has disclosed $19.3M raised across 2 rounds.
- Where is RenBio headquartered?
- RenBio is headquartered in Long Island City, US.